BioSpace News Archive

Alaya.bio, a biotechnology company developing a novel polymeric delivery platform towards in situ cell therapies, announces a collaboration with CAR-T pioneer Michel Sadelain, MD, PhD, Stephen and Barbara Friedman Chair and Director, Center for Cell Engineering at the Memorial Sloan Kettering Cancer Center (MSK) in New York City.

Natera, Inc. announced that new data on its personalized and tumor-informed molecular residual disease test, Signatera™, will be presented at the American Society of Clinical Oncology’s 2024 Gastrointestinal Cancers Symposium, taking place January 18 – 20, 2024 in San Francisco, California.

Hoth Therapeutics, Inc. (NASDAQ: HOTH) announced today that it has received U.S. Food and Drug Administration (FDA) clearance to implement a number of protocol amendments to its ongoing clinical trial for HT-001, which is being developed as a potential treatment for cancer patients undergoing treatment of skin toxicities associated with Epidermal Growth Factor Receptor Inhibitors (EGFRI).

Lisata Therapeutics, Inc. today announced that David J. Mazzo, Ph.D., President and Chief Executive Officer of Lisata, will deliver a company presentation at the upcoming Sequire Investor Summit being held January 23-25, 2024.

XOMA Corporation announced it has acquired an economic interest in DSUVIA® from Talphera, Inc., for $8 million.

Surrozen, Inc. announced that enrollment for the SZN-043 Phase 1a clinical trial in patients with chronic liver disease and healthy volunteers is complete.

Adial Pharmaceuticals, Inc. today announced the appointment of Tony Goodman as Chief Operating Officer.

Halozyme Therapeutics, Inc. (NASDAQ: HALO) (“Halozyme”) today announced that argenx received approval from Japan’s Ministry of Health, Labour and Welfare (MHLW) for VYVDURA ® (efgartigimod alfa and hyaluronidase-qvfc) injection co-formulated with Halozyme’s ENHANZE® drug delivery technology for subcutaneous (SC) use for the treatment of adult patients with generalized myasthenia gravis (gMG).

Quantum-Si Incorporated announced that it has entered into an agreement with a new distributor who will make the company’s protein sequencing instrument, Platinum® available for the first time in Japan.

Vivtex Corporation (“Vivtex”) and AI Proteins, Inc., a growing biotechnology company that utilizes computational de novo protein design to create novel therapeutic miniproteins, today announced they have entered a strategic R&D collaboration to develop novel, oral biologic therapies for inflammatory diseases.